SF3B1 gene mutations confer an improved clinical outcome in patients, while TP53, RUNX1, ASXL1, ETV6, and EZH2 are predictors of worse outcomes and are associated with inferior OS in MDS cases independent of other recognized risk factors [31]. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.